0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Special Feature |

Image of the Month—Diagnosis FREE

[+] Author Affiliations

Section Editor: Carl E. Bredenberg, MD

More Author Information
Arch Surg. 2010;145(12):1212. doi:10.1001/archsurg.2010.268-b.
Text Size: A A A
Published online

The patient had a 15 × 13-cm, lobulated mass arising from the dome of the bladder. A partial cystectomy with removal of the tumor, iliac node dissection, and primary repair of the bladder was carried out. The patient had an uncomplicated course and was discharged on the third postoperative day with a urinary catheter. The pathological finding on the resected specimen was embryonal, botryoid rhabdomyosarcoma involving the right iliac nodes with negative margins (pT2, pN1, pMX).

Childhood rhabdomyosarcoma, a malignant tumor of skeletal muscle origin, accounts for approximately 3.5% of cancer cases among children aged 0 to 14 years.1The most common primary sites are the genitourinary tract, extremities, and head and neck. Although most cases are sporadic, some are associated with Li-Fraumeni, Costello, Beckwith-Wiedemann, and Noonan syndromes. Rhabdomyosarcoma has been histologically classified into embryonal (60%-70%), alveolar (20%), and pleomorphic (anaplastic) subtypes.

The treatment of rhabdomyosarcoma requires multimodality therapy including surgery for local tumor control, systemic chemotherapy, and radiation. The Soft Tissue Sarcoma Committee of the Children's Oncology Group develops treatment protocols incorporating surgicopathological group, primary tumor site, regional lymph node status, and presence or absence of metastases. The surgical treatment involves complete resection of the primary tumor with a surrounding margin of normal tissue and lymph node sampling of the draining nodal basin provided there is no major functional or cosmetic impairment.2

The prognosis depends on the age of the patient, stage, group, location of the primary tumor, and histological findings.3Patients aged between 1 and 9 years have the best overall prognosis.4Rhabdomyosarcoma involving the nonparameningeal head and neck, paratestis, vagina, and biliary tract carry a better prognosis, whereas tumors larger than 5 cm and metastatic disease at diagnosis are associated with poor long-term survival. Overall, it is a curable disease with greater than 70% 5-year survival in children with localized disease receiving multimodal therapy.5

Return to Quiz Case.

Correspondence:Antony Joseph, MBBS, MRCSEd, Department of Surgery, West Virginia University Hospital, PO Box 9238 HSC, 1 Medical Center Dr, Morgantown, WV 26505 (drantonyjoseph@gmail.com).

Accepted for Publication:August 31, 2009.

Author Contributions:Study concept and design: Joseph. Analysis and interpretation of data: Vaughan. Drafting of the manuscript: Joseph. Critical revision of the manuscript for important intellectual content: Vaughan. Administrative, technical, and material support: Joseph. Study supervision: Vaughan.

Financial Disclosure:None reported.

Gurney  JGSeverson  RKDavis  SRobison  LL Incidence of cancer in children in the United States: sex-, race-, and 1-year age-specific rates by histologic type. Cancer 1995;75 (8) 2186- 2195
PubMed
Leaphart  CRodeberg  D Pediatric surgical oncology: management of rhabdomyosarcoma. Surg Oncol 2007;16 (3) 173- 185
PubMed
Lawrence  W  JrGehan  EAHays  DMBeltangady  MMaurer  HM Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II). J Clin Oncol 1987;5 (1) 46- 54
PubMed
Joshi  DAnderson  JRPaidas  CBreneman  JParham  DMCrist  WSoft Tissue Sarcoma Committee of the Children's Oncology Group, Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatr Blood Cancer 2004;42 (1) 64- 73
PubMed
Crist  WMAnderson  JRMeza  JL  et al.  Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001;19 (12) 3091- 3102
PubMed

Figures

Tables

References

Gurney  JGSeverson  RKDavis  SRobison  LL Incidence of cancer in children in the United States: sex-, race-, and 1-year age-specific rates by histologic type. Cancer 1995;75 (8) 2186- 2195
PubMed
Leaphart  CRodeberg  D Pediatric surgical oncology: management of rhabdomyosarcoma. Surg Oncol 2007;16 (3) 173- 185
PubMed
Lawrence  W  JrGehan  EAHays  DMBeltangady  MMaurer  HM Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II). J Clin Oncol 1987;5 (1) 46- 54
PubMed
Joshi  DAnderson  JRPaidas  CBreneman  JParham  DMCrist  WSoft Tissue Sarcoma Committee of the Children's Oncology Group, Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatr Blood Cancer 2004;42 (1) 64- 73
PubMed
Crist  WMAnderson  JRMeza  JL  et al.  Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001;19 (12) 3091- 3102
PubMed

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles